Â鶹ŮÓÅ

The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination treatment for a type of non-small cell lung cancer, setting up a challenge for AstraZeneca's blockbuster drug Tagrisso. The approval allows the use of the cancer drug, Rybrevant, in combination with J&J's existing drug, lazertinib, as a first-line treatment for non-small cell lung cancer (NSCLC) patients with a mutated form of a gene called EGFR. NSCLC is the most common type of lung cancer. (Satija and Santhosh, 8/20)

Plaintiffs claiming that Kenvue's popular painkiller Tylenol causes attention deficit hyperactivity disorder (ADHD) in the children of mothers who took it while pregnant have lost a last ditch bid to revive their claims after a judge rejected their last remaining expert witness. (Pierson, 8/20)

Johnson & Johnson said on Tuesday it would buy privately held V-Wave for up to $1.7 billion, the healthcare conglomerate's second deal this year aimed at boosting its presence in the market for heart disease devices. J&J said it will pay $600 million upfront, with potential payments of up to $1.1 billion contingent on regulatory and commercial milestones. (8/20)

Next week, the biopharma world will see eagerly awaited results from a trial that could shape care for patients with an increasingly common heart condition — and determine which companies stand to reap billions. (Chen, Joseph and Feuerstein, 8/20)

A bipartisan group of House lawmakers is scrutinizing hundreds of clinical trials they say U.S. drug companies conducted with medical centers connected to China's military over the last decade. (Goldman, 8/21)